Last checked at 19 Nov 2021 07:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY EUROPEAN ECONOMIC AREA STATE (OTHER THAN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED) OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT WOULD BE UNLAWFUL.
19 November 2021
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Admission to trading on AIM and first day of dealings
Further to its previous announcements, Life Science REIT, the first London listed real estate investment trust focused on UK life science properties, is pleased to announce the admission of its entire issued ordinary share capital to trading on the AIM market of the London Stock Exchange at 8.00 a.m. today under the ticker "LABS" ("Admission").
The Company's unaudited net assets on Admission will be approximately £343 million (after the deduction of the expenses of, and incidental to, the formation of the Company, the Issue and Admission).
For the purposes of the Disclosure Guidance and Transparency Rules, the total number of ordinary shares with voting rights in the Company with effect from 19 November 2021 will be 350,000,000. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change of their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Further information on Life Science REIT is available on its website: http://lifesciencereit.co.uk.
Unless the context otherwise requires, capitalised terms used in this announcement have the meanings given to them in the prospectus published by the Company on 21 October 2021.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Ironstone Asset Management - Investment Adviser
Simon Farnsworth via Buchanan below
Panmure Gordon - Nominated Adviser and Joint Broker
Investment Banking
Atholl Tweedie +44 20 7886 2962
Sapna Shah +44 20 7886 2783
Philip Shields +44 20 7886 2862
Chloe Ponsonby +44 20 7886 2796
Sales
Tom Scrivens +44 20 7886 2648
David Hawkins +44 20 7886 2702
Jefferies International Limited - Joint Broker
Tom Yeadon +44 207 548 4329
Andrew Morris +44 207 029 8173
Oliver Nott +44 207 548 4675
Buchanan - Financial PR
Mark Court +44 20 7466 5125
Henry Wilson +44 20 7466 5111
Verity Parker +44 20 7466 5197
LifeSciencereit@buchanan.uk.com
This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offer of securities is being made in the United States.
Notes to editors
Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector.
The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to tenants operating in the life science sector in the UK.
Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk